Is APRE or ARGX more undervalued in 2026?

CirclFi compares Aprea Therapeutics, Inc. (APRE) and argenx SE (ARGX) using 13 institutional-grade valuation models. APRE has a Quality of Company score of 4.5/10 while ARGX scores 2.0/10.

Which is a better buy — APRE or ARGX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do APRE and ARGX valuations compare?

APRE at $0.93 and ARGX at $838.49 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

APRE vs ARGX Valuation Comparison 2026 — Intrinsic Value Analysis

APRE

Biotechnology

Aprea Therapeutics, Inc.

Quality

4.5

out of 10

Value Trap

SAFE

Price

$0.93

Last close

Models

8/13

Active

ARGX

Biotechnology

argenx SE

Quality

2.0

out of 10

Value Trap

—

Price

$838.49

Last close

Models

13/13

Active

Model-by-Model Comparison

Model	Type	APRE Fair Value	APRE Upside	ARGX Fair Value	ARGX Upside
Bayesian DCF	Intrinsic	$2.30	+147.6%	$279.55	-66.7%
Earnings Power Value	Intrinsic	—	—	$363.38	-53.4%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.80	-14.3%	$1161.33	+38.5%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for APRE vs ARGX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

APRE vs ARGX — Which Stock Is More Undervalued?

APRE scores higher with a 4.5/10 quality rating vs ARGX's 2.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Aprea Therapeutics, Inc. (APRE) and argenx SE (ARGX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

APRE currently trades at $0.93 with a QOC of 4.5/10, while ARGX trades at $838.49 with a QOC of 2.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).